Description
The India biosimilars market was valued at USD 1.2 billion in 2025 and is projected to reach USD 3.8 billion by 2032, expanding at a CAGR of 17.9% during the forecast period. Biosimilars are biologic medicines that demonstrate high similarity to already approved reference biologics in terms of quality, safety, and clinical efficacy while offering a more cost-effective therapeutic alternative. These products are developed through advanced biotechnological processes and are widely used in the treatment of chronic and life-threatening conditions, including cancer, autoimmune diseases, diabetes, hematological disorders, and hormonal deficiencies. The Indian biosimilars market has emerged as one of the fastest-growing segments of the country’s biopharmaceutical industry, supported by strong domestic manufacturing capabilities, an expanding regulatory framework, and increasing demand for affordable biologic therapies. The market also benefits from India’s position as a global manufacturing hub, enabling companies to serve both domestic healthcare needs and export markets.
Market growth is being driven by the increasing burden of chronic diseases, rising healthcare expenditure, wider adoption of biologic therapies, and government initiatives aimed at improving patient access to affordable treatments. The expiry of patents for several blockbuster biologics has created significant opportunities for domestic manufacturers to introduce biosimilar alternatives across multiple therapeutic areas. At the same time, continuous investments in biologics manufacturing facilities, recombinant technologies, mammalian cell culture systems, and advanced process development are enhancing production efficiency and product quality. Strategic collaborations, licensing agreements, capacity expansion, and international commercialization initiatives are further strengthening India’s competitive position in the global biosimilars ecosystem. Over the forecast period, the market is expected to witness sustained expansion as innovation, regulatory harmonization, and broader physician acceptance continue to accelerate biosimilar adoption across hospitals, specialty care centers, and healthcare institutions.
Key Highlights of the Report
• In terms of product, recombinant glycosylated proteins dominate the India biosimilars market, supported by their extensive use in monoclonal antibodies, erythropoietin, fusion proteins, and other biologics used for treating high-burden chronic diseases.
• The mammalian cell culture systems segment is projected to register the fastest growth, driven by increasing development of complex biosimilars, particularly monoclonal antibodies and advanced recombinant biologics requiring sophisticated manufacturing platforms.
• Based on application, the hematology segment accounts for the largest share of the market due to widespread use of erythropoietin and granulocyte colony-stimulating factor (G-CSF) therapies for anemia, neutropenia, and supportive oncology care.
• Among manufacturing types, in-house manufacturing remains the leading segment as established Indian biopharmaceutical companies continue to invest in vertically integrated research, development, manufacturing, and commercialization capabilities.
• Contract research and manufacturing services (CRAMS) are expected to witness robust growth as emerging biosimilar developers increasingly outsource specialized development and production activities to reduce capital investment and accelerate commercialization.
• By technology, recombinant DNA technology dominates the market owing to its well-established role in producing insulin, growth hormones, interferons, and colony-stimulating factors, supported by India’s extensive expertise in recombinant biologics manufacturing.
• Hospital pharmacies represent the dominant distribution channel, benefiting from higher administration of biologics within hospital settings, greater physician supervision, and increasing institutional procurement of biosimilar therapies.
• The market continues to benefit from India’s strong manufacturing ecosystem, skilled scientific workforce, cost-efficient production capabilities, and increasing regulatory maturity, strengthening its position as a global biosimilars development hub.
• Expanding physician confidence, growing patient awareness regarding biosimilar safety and efficacy, and broader healthcare access initiatives are supporting greater penetration across multiple therapeutic indications.
• Strategic partnerships, licensing collaborations, technology transfer agreements, and international commercialization initiatives are enabling Indian manufacturers to expand their presence across regulated global markets.
• Continuous investments in biologics manufacturing infrastructure, advanced bioprocessing technologies, and quality management systems are enhancing production efficiency and regulatory compliance across the industry.
• The competitive landscape remains moderately concentrated, with Biocon Biologics leading the market, while the top five companies maintain a significant collective presence through diversified product portfolios and extensive manufacturing capabilities.
Key Company Profiles
• Biocon Biologics
• Dr. Reddy’s Laboratories
• Intas Pharmaceuticals
• Lupin Limited
• Reliance Life Sciences
• Sun Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris India
• Zydus Lifesciences
• Cadila Pharmaceuticals
• Stelis Biopharma
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
